Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Interpace Biosciences, Inc. (IDXG) had Return on Tangible Equity of -301.37% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$11.52M |
|
$1.65M |
|
$4.14M |
|
$7.37M |
|
$9.69M |
|
$1.83M |
|
$-0.06M |
|
$1.77M |
|
$1.77M |
|
$1.75M |
|
$1.75M |
|
$1.65M |
|
$1.75M |
|
$1.83M |
|
$2.03M |
|
4.42M |
|
27.70M |
|
$0.37 |
|
$0.06 |
|
| Balance Sheet Financials | |
$11.65M |
|
$1.28M |
|
$2.84M |
|
$14.49M |
|
$8.68M |
|
-- |
|
$6.40M |
|
$15.08M |
|
$-0.58M |
|
$-0.58M |
|
$-0.58M |
|
4.42M |
|
| Cash Flow Statement Financials | |
$1.24M |
|
-- |
|
$-1.50M |
|
$1.46M |
|
$1.20M |
|
$-0.27M |
|
$0.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.34 |
|
-- |
|
-- |
|
-- |
|
-4.75 |
|
64.00% |
|
15.88% |
|
15.88% |
|
-- |
|
15.39% |
|
14.30% |
|
$1.24M |
|
-- |
|
-- |
|
-- |
|
0.79 |
|
-- |
|
1.31 |
|
68.53 |
|
-301.37% |
|
|
Return on Tangible Equity |
-301.37% |
12.10% |
|
-301.37% |
|
$-0.13 |
|
$0.04 |
|
$0.04 |
|